Stop unannounced home inspections of those with special needs
This situation occurred with Plain Township resident Catherine Smith, who along with two other women, joined a state lawsuit challenging an Ohio Department of Developmental Disabilities directive that allows the visits.
As someone with siblings who have special needs, I understand the dedication required for their care, including various therapies and learning programs. Ensuring adequate support for these children is crucial, and it's frustrating when someone shows up without proper notice, similar to the practices of Child Protective Services. Catherine noted that the employee made inappropriate comments about her daughter's drooling and reprimanded her for answering the door too slowly.
Such remarks are not only unprofessional but also irrelevant to the client's care. Arriving with an outdated schedule while expecting immediate compliance is unreasonable. Proper notification allows parents to prepare and clear their schedules, making it easier for everyone involved.
I commend Catherine for pursuing legal action, as services like Medicaid often seek ways to minimize their financial responsibilities, potentially harming children in need. Essential equipment like braces and wheelchairs can be costly, and instead of supporting families, there is a tendency to undermine their benefits. It's vital for media outlets to continue reporting on these issues, as they impact families significantly and deserve more attention from the community.Angelica Austin, Jackson Township
This article originally appeared on The Repository: Stop unannounced home inspections of those with special needs | Letter
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
30 minutes ago
- CBS News
Weiss Hospital could face closure when kicked off Medicare, Medicaid Friday, report says
Weiss Hospital in Chicago's Uptown neighborhood will be removed from the Medicare and Medicaid programs Friday, and a report suggests it could face closure. The Department of Health and Human Services is removing Weiss from the federal health care programs, saying the hospital failed to meet their standards of care. A nurse in the hospital's Emergency Department told the Chicago Sun-Times they expect to shut down Friday morning at 7 a.m. They said they were informed of that decision by their supervisor, and also noted no staff schedule has been set beyond Saturday. CBS News Chicago has leaned more about the exact reasons the hospital was deemed noncompliant with federal rules. Notably, a July 12 report by the Centers for Medicare and Medicaid Services did not cite the hospital's broken air conditioning as a reason. Rather, the report detailed multiple failures related to nursing care, along with a failure related to pharmaceutical record-keeping.
Yahoo
an hour ago
- Yahoo
Epicured Partners with Staten Island Performing Provider System to Provide Nutrition Services Under the New York State $7.5B Medicaid Waiver
GLEN COVE, N.Y., Aug. 7, 2025 /PRNewswire/ -- Epicured Inc., the leading provider of medically tailored nutrition solutions, is proud to announce its strategic partnership with Staten Island Performing Provider System (Staten Island PPS) to meet the growing demand for nutrition services under New York State's $7.5 billion Section 1115 Medicaid Waiver program. This strategic partnership represents a significant milestone in Epicured's mission to deliver clinically appropriate, home-delivered meals, pantry boxes, and nutrition counseling services to Medicaid members across the state. In collaboration with Staten Island PPS, Epicured is improving health outcomes, addressing health disparities, and advancing a "whole-person care" approach for New York's most vulnerable communities. "Staten Island PPS has been an incredible partner in this work," said Richard Bennett, CEO and Co-founder of Epicured. "Their commitment to unlocking access to essential services, combined with our capacity to deliver clinically appropriate, scalable nutrition solutions, is already beginning to drive meaningful change in the lives of many." Since the Waiver's launch in January 2025, Epicured has expanded its logistics, operations, and care delivery infrastructure to quickly serve Medicaid members statewide. Epicured's personalized services include home-delivered medically tailored meals (MTMs), pantry and grocery boxes, and one-on-one nutrition counseling, all designed to meet the clinical needs cultural preferences of each patient. By partnering with Staten Island PPS, Epicured ensures its services reach those who need them most. "Epicured's commitment to quality, scalability, and culturally relevant nutrition has made them a vital partner in our work," said Joe Conte, Executive Director of Staten Island PPS. "Together, we are bringing dignity and real change to thousands of Medicaid members." Over the past six months, Epicured has already had an impact on Medicaid members by making it easier to adopt healthier eating habits through the delivery of clinically appropriate meal and pantry boxes. While meeting each member's daily nutritional needs, Epicured also offers a wide range of medically tailored therapeutic journeys to manage chronic conditions such as diabetes, cardiovascular disease, as well as the special needs of pregnant and postpartum women. These services are designed to meet the unique needs of a diverse population including infants and elderly, ensuring that personalized, condition-specific nutrition is accessible at every stage of life and every stage of health. Feedback from program participants has been overwhelmingly positive, with many sharing the impact the program has had on their health and overall quality of life: "I recommend Epicured to anyone who needs help transitioning to a healthy and different way of eating," said a member in the Stapleton neighborhood of Staten Island. "The portions are great, and you'll be amazed at the different meals." A resident of South Beach public housing shared, "This program is great because I have trouble walking and standing for long periods. I've been telling everyone because it's a great program." Epicured looks forward to continuing to offer its food is medicine expertise to treat members with dignity, reduce health disparities, improve outcomes, and provide easier access to adequate and appropriate nutrition, healthcare's most essential building block. If you are a Medicaid Member, you may be eligible for free services under the 1115 waiver. Visit to complete a self-screening form or call (917)830-1140 to get screened. Contact Information: Alexandra Weil, Epicured, press@ About Epicured Inc. Epicured is on a mission to combat and prevent chronic disease, translating scientific research into high-quality food products nationwide. Our evidence-based approach brings the best of the clinical and culinary worlds together to help people eat better, feel better, and live better one meal at a time. As the leading Food is Medicine company, Epicured is working to redefine nutrition's role in the American healthcare industry and Americans' health. We work with individuals, health plans, healthcare providers, and life sciences companies to design innovative and delicious solutions to some of the world's toughest problems. Find out more about our vision for advancing food is medicine by visiting or follow us on LinkedIn. About Staten Island Performing Provider System (SI PPS) Staten Island Performing Provider System (SI PPS) is a non-profit public health organization founded in 2014 under the New York State Department of Health Medicaid 1115 waiver amendment known as the Delivery System Reform Incentive Payment (DSRIP) program. Under that program, SI PPS received funding to build a network of medical, behavioral health, and social service agencies tasked with implementing projects to improve health outcomes, improve quality of care, and reduce costs for the Medicaid program. SI PPS succeeded in meeting the State's targets for reducing avoidable hospital utilization and improving access to medical and behavioral health, among others. At the end of the program, SI PPS earned high performance funding which has been invested back into network partners who have continued to expand upon population health improvement 2024, New York State received an extension of their Medicaid 1115 waiver amendment to implement a new initiative called New York Health Equity Reform. Under this waiver, SI PPS became the lead entity in Richmond County to develop a Social Care Network. The goal of the Social Care Network is to expand and enhance the capability of our network to provide health-related social needs screening for all Medicaid members, improve the coordination and delivery of social care services, and reduce health disparities. View original content to download multimedia: SOURCE Epicured Inc. Sign in to access your portfolio
Forbes
an hour ago
- Forbes
Coverage Of Weight Loss Drugs By Medicaid Plans Continues To Lag
California recently passed a budget for 2025-2026 that eliminates Medicaid coverage for GLP-1 agonists for weight loss. Other states are considering similar cuts. States are struggling to close gaps in budgets. Enactment of The Big Beautiful Bill will likely add pressure on budget finances. It's hard to envision a scenario in which state Medicaid agencies expand coverage of weight loss treatments in the short term. About 40% of adult Americans are considered obese. Rates of obesity have been steadily on the rise since 1980. The Harvard T.H. Chan School of Public Health reminds us that obesity increases the risk of developing conditions such as diabetes, heart disease, osteoarthritis and several cancers. Medications known as glucagon-like peptide-1 agonists, or GLP-1s, have become very popular as weight loss agents. Taken in accordance with the instructions on the label and an appropriate diet and exercise regimen, GLP-1s are effective at lowering a person's weight. However, payers in both the commercial and public sectors often balk at coverage. Commercial insurance coverage is improving but still isn't universal by any means, whether in the employer-sponsored segment or individual market. In the federal insurance program for the elderly and some disabled persons, Medicare, coverage of GLP-1s for weight loss alone is prohibited, though obese patients can get the semaglutide-based product, Wegovy, covered for heart disease. Medicaid, a federal-state partnership that provides health coverage for low-resourced people, generally doesn't reimburse GLP-1s for obesity. Only 14 states cover obesity medications in their state Medicaid plans. And like California, other states have proposed cutting coverage for obesity medications or have already done so, whether in the Medicaid program itself or state employee plans. For example, North Carolina and West Virginia have recently eliminated coverage of GLP-1s for weight loss for state employees due to cost concerns. With significant Medicaid cuts in federal budget outlays as a result of passage of The Big Beautiful Bill, it is likely more states will follow suit. The law severely restricts how states pay for their share of Medicaid costs. To illustrate, states have long used healthcare provider taxes and certain special payment arrangements to fund their portion of the program. Yet the new legislation limits these financing tools, effectively shifting hundreds of billions in costs to state budgets. States that do opt to cover various weight loss treatments, including medications, nutrition programs and bariatric surgery, almost invariably deploy restrictive eligibility requirements around things like body mass indices and the presence of co-morbidities, along with the use of prior authorization and step edits. This means, for instance, that individuals wanting to access treatments must attest to 'increased exercise activity' and submit documentation proving that they've tried and failed to lose weight after receiving nutrition counseling and going on a strict, low-calorie diet. In light of budget constraints, steep cuts to a wide range of Medicaid benefits are probable in the short term. This may come in the form of even more severe limits on coverage of medicines and other healthcare technologies, including obesity treatments. It's possible that through a voluntary demonstration project that the Centers for Medicare and Medicaid Services announced last month, some state Medicaid agencies could soon elect to cover these drugs for 'weight management.' But the plan has not been finalized. Nor have any details been divulged besides the fact that it would commence in April of next year for Medicaid. Without information on how state programs would be incentivized to sign up, it's unclear who would be interested. The perennial issue for all types of payers is money. Once these therapeutics are covered by insurance, they tend to blow up budgets. Many payers in the commercial sector cite serious budgetary concerns. A survey released this spring of employer-based plans shows that GLP-1 drugs used for obesity account for an average of 10.5% of total annual claims. And if Medicare were to lift its prohibition on coverage, it would cost the program a cumulative $35 billion from 2026-2034. While the estimates included possible savings from improved health, these were not nearly sufficient to offset the costs of the medications. Such projected expenses haven't been calculated specifically for Medicaid. But the churn or enrollee turnover is so high in Medicaid that any longer-term, downstream cost savings would be very hard to come by, further exacerbating the budgetary problem. While cost is a primary consideration for payers, lack of persistence on GLP-1s is another reason for hesitance to reimburse weight loss drugs. Patients who are treated with GLP-1s tend to discontinue at a relatively high rate. One study cited by federal government policymakers found that approximately 53% of patients with overweight or obesity taking semaglutide-based products didn't persist on treatment past two months. Starting and stopping on these medicines so soon yields little or no benefit to patients and only adds costs for payers. It's possible that employers, commercial insurers and payers in the public sector—including Medicaid—decide to eventually revisit their coverage decisions if net prices of GLP-1s decrease sufficiently, combined with more data showing the benefits of weight loss drugs when taken consistently and persistently in conjunction with an appropriate dietary and exercise regimen. Until that time, however, coverage will continue to be a major hurdle.
